US political rhetoric is weighing on short-term sentiment in the healthcare sector as concerns grow about potential drug pricing reform and the impact of Medicare for All, Polar Capital's Jamie Douglas said, but added that despite these short-term concerns, the fundamentals for the healthcare industry are strong.
The manager of the $84.4m Polar Capital Healthcare Blue Chip fund said the affordability of healthcare will be a focus for both political parties with the selection process for the Democratic candidate to take on US President Donald Trump underway. Polar hires ex-Neptune's Unwin for technology team "Addressing the high cost of pharmaceuticals in the US is something that appears to have bipartisan support and we believe there could be some progress on drug pricing in the coming months," Douglas said. "While the exact mechanics are difficult to predict at this stage, the uncertainty doe...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
